Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 1
1956 1
1957 1
1958 2
1960 2
1961 1
1994 1
1995 1
1996 10
1997 24
1998 27
1999 32
2000 36
2001 65
2002 90
2003 110
2004 125
2005 143
2006 134
2007 133
2008 129
2009 131
2010 128
2011 144
2012 127
2013 131
2014 127
2015 124
2016 106
2017 116
2018 94
2019 100
2020 103
2021 50
Text availability
Article attribute
Article type
Publication date

Search Results

2,305 results
Results by year
Filters applied: . Clear all
Page 1
Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial.
Cuzick J, Sestak I, Forbes JF, Dowsett M, Cawthorn S, Mansel RE, Loibl S, Bonanni B, Evans DG, Howell A; IBIS-II investigators. Cuzick J, et al. Lancet. 2020 Jan 11;395(10218):117-122. doi: 10.1016/S0140-6736(19)32955-1. Epub 2019 Dec 12. Lancet. 2020. PMID: 31839281 Free PMC article. Clinical Trial.
Here, we report blinded long-term follow-up results for the IBIS-II trial, which compared anastrozole with placebo, with the objective of determining the efficacy of anastrozole for preventing breast cancer (both invasive and ductal carcinoma in situ) in the post-tr …
Here, we report blinded long-term follow-up results for the IBIS-II trial, which compared anastrozole with placebo, with the objectiv …
Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer.
Mehta RS, Barlow WE, Albain KS, Vandenberg TA, Dakhil SR, Tirumali NR, Lew DL, Hayes DF, Gralow JR, Linden HH, Livingston RB, Hortobagyi GN. Mehta RS, et al. N Engl J Med. 2019 Mar 28;380(13):1226-1234. doi: 10.1056/NEJMoa1811714. N Engl J Med. 2019. PMID: 30917258 Free PMC article. Clinical Trial.
We now report final survival outcomes. METHODS: We randomly assigned patients to receive either anastrozole or fulvestrant plus anastrozole. Randomization was stratified according to adjuvant tamoxifen use. ...The incidence of long-term toxic effects of grade 3 to 5 …
We now report final survival outcomes. METHODS: We randomly assigned patients to receive either anastrozole or fulvestrant plus an
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.
Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, Forbes JF; ATAC/LATTE investigators. Cuzick J, et al. Lancet Oncol. 2010 Dec;11(12):1135-41. doi: 10.1016/S1470-2045(10)70257-6. Epub 2010 Nov 17. Lancet Oncol. 2010. PMID: 21087898 Clinical Trial.
In hormone-receptor-positive patients, absolute differences in time to recurrence between anastrozole and tamoxifen increased over time (27% at 5 years and 43% at 10 years) and recurrence rates remained significantly lower on anastrozole than tamoxifen after treatme …
In hormone-receptor-positive patients, absolute differences in time to recurrence between anastrozole and tamoxifen increased over ti …
Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR(+)/HER2(-) Breast Cancer.
Hurvitz SA, Martin M, Press MF, Chan D, Fernandez-Abad M, Petru E, Rostorfer R, Guarneri V, Huang CS, Barriga S, Wijayawardana S, Brahmachary M, Ebert PJ, Hossain A, Liu J, Abel A, Aggarwal A, Jansen VM, Slamon DJ. Hurvitz SA, et al. Clin Cancer Res. 2020 Feb 1;26(3):566-580. doi: 10.1158/1078-0432.CCR-19-1425. Epub 2019 Oct 15. Clin Cancer Res. 2020. PMID: 31615937 Free PMC article. Clinical Trial.
PURPOSE: neoMONARCH assessed the biological effects of abemaciclib in combination with anastrozole in the neoadjuvant setting. PATIENTS AND METHODS: Postmenopausal women with stage I-IIIB HR(+)/HER2(-) breast cancer were randomized to a 2-week lead-in of abemaciclib, an
PURPOSE: neoMONARCH assessed the biological effects of abemaciclib in combination with anastrozole in the neoadjuvant setting. PATIEN …
Daily subcutaneous testosterone for management of testosterone deficiency.
Yazdani N, Matthews Branch S. Yazdani N, et al. Front Biosci (Elite Ed). 2018 Mar 1;10:334-343. doi: 10.2741/e825. Front Biosci (Elite Ed). 2018. PMID: 29293461
To determine the effectiveness of therapy using the Daily Subcutaneous Testosterone (DST) method in combination with human chorionic gonadotropin (hCG) and an aromatase inhibitor (anastrozole), a retrospective analysis was conducted of men diagnosed and treated for TD. ... …
To determine the effectiveness of therapy using the Daily Subcutaneous Testosterone (DST) method in combination with human chorionic gonadot …
Subcutaneous Testosterone Anastrozole Therapy in Men: Rationale, Dosing, and Levels on Therapy.
Glaser RL, York AE. Glaser RL, et al. Int J Pharm Compd. 2019 Jul-Aug;23(4):325-339. Int J Pharm Compd. 2019. PMID: 31315085
Correlations between patient demographics, dosing, and serum levels on therapy were evaluated. Mean testosterone dose was 1827 262 mg. Mean anastrozole dose was 15.3 3.2 mg with the majority of men receiving 16 mg of subcutaneous anastrozole. ...There were no advers …
Correlations between patient demographics, dosing, and serum levels on therapy were evaluated. Mean testosterone dose was 1827 262 mg. Mean …
Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole action.
Cairns J, Ingle JN, Dudenkov TM, Kalari KR, Carlson EE, Na J, Buzdar AU, Robson ME, Ellis MJ, Goss PE, Shepherd LE, Goodnature B, Goetz MP, Weinshilboum RM, Li H, Bari MG, Wang L. Cairns J, et al. JCI Insight. 2020 Aug 20;5(16):e137571. doi: 10.1172/jci.insight.137571. JCI Insight. 2020. PMID: 32701512 Free PMC article. Clinical Trial.
Mechanistically, CSMD1 regulates CYP19 expression in an SNP- and drug-dependent fashion, and this regulation is different among 3 AIs: anastrozole, exemestane, and letrozole. Overexpression of CSMD1 sensitized AI-resistant cells to anastrozole but not to the other 2 …
Mechanistically, CSMD1 regulates CYP19 expression in an SNP- and drug-dependent fashion, and this regulation is different among 3 AIs: an
Combination therapy with clomiphene citrate and anastrozole is a safe and effective alternative for hypoandrogenic subfertile men.
Alder NJ, Keihani S, Stoddard GJ, Myers JB, Hotaling JM. Alder NJ, et al. BJU Int. 2018 Oct;122(4):688-694. doi: 10.1111/bju.14390. Epub 2018 Jun 6. BJU Int. 2018. PMID: 29873446
OBJECTIVES: To assess the efficacy and safety of combination therapy with clomiphene citrate (CC) and anastrozole (AZ) for male hypoandrogenism. PATIENTS AND METHODS: We identified patients treated with a combination of CC + AZ in the period 2014 to 2017. ...
OBJECTIVES: To assess the efficacy and safety of combination therapy with clomiphene citrate (CC) and anastrozole (AZ) for male hypoa …
Breast Cancer Risk-Reducing Medications.
Graham D, DiNome ML, Ganz PA. Graham D, et al. JAMA. 2020 Jul 21;324(3):310. doi: 10.1001/jama.2020.11784. JAMA. 2020. PMID: 32692388 No abstract available.
Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study.
Robertson JF, Llombart-Cussac A, Rolski J, Feltl D, Dewar J, Macpherson E, Lindemann J, Ellis MJ. Robertson JF, et al. J Clin Oncol. 2009 Sep 20;27(27):4530-5. doi: 10.1200/JCO.2008.21.1136. Epub 2009 Aug 24. J Clin Oncol. 2009. PMID: 19704066 Clinical Trial.
Objective response rate (ORR) was also similar between treatments: fulvestrant HD, 36.0%; anastrozole, 35.5%. Time to progression (TTP) was significantly longer for fulvestrant versus anastrozole (median TTP not reached for fulvestrant HD v 12.5 months for anastr
Objective response rate (ORR) was also similar between treatments: fulvestrant HD, 36.0%; anastrozole, 35.5%. Time to progression (TT …
2,305 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page